127 related articles for article (PubMed ID: 37741703)
21. Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma.
Hiyama E; Hiyama K; Yokoyama T; Fukuba I; Yamaoka H; Shay JW; Matsuura Y
Clin Cancer Res; 1999 Mar; 5(3):601-9. PubMed ID: 10100712
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic Targeting of
Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
[TBL] [Abstract][Full Text] [Related]
23. Application of fluorescence in situ hybridization to detect N-myc (MYCN) gene amplification on paraffin-embedded tissue sections of neuroblastomas.
Hachitanda Y; Saito M; Mori T; Hamazaki M
Med Pediatr Oncol; 1997 Aug; 29(2):135-8. PubMed ID: 9180916
[TBL] [Abstract][Full Text] [Related]
24. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.
Duan XF; Zhao Q
J Pediatr Hematol Oncol; 2018 Jan; 40(1):1-6. PubMed ID: 28452859
[TBL] [Abstract][Full Text] [Related]
25.
Bhardwaj N; Rohilla M; Trehan A; Bansal D; Kakkar N; Srinivasan R
J Clin Pathol; 2023 Sep; 76(9):599-605. PubMed ID: 35414524
[TBL] [Abstract][Full Text] [Related]
26. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
27. Telomere maintenance is pivotal for high-risk neuroblastoma.
Hertwig F; Peifer M; Fischer M
Cell Cycle; 2016; 15(3):311-2. PubMed ID: 26653081
[No Abstract] [Full Text] [Related]
28. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
29. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.
Ma Y; Lee JW; Park SJ; Yi ES; Choi YB; Yoo KH; Sung KW; Koo HH
J Korean Med Sci; 2016 Sep; 31(9):1392-6. PubMed ID: 27510381
[TBL] [Abstract][Full Text] [Related]
30. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
31. Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma.
Yu EY; Cheung IY; Feng Y; Rabie MO; Roboz GJ; Guzman ML; Cheung NV; Lue NF
Neoplasia; 2019 Jul; 21(7):689-701. PubMed ID: 31128432
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
[TBL] [Abstract][Full Text] [Related]
33. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
[TBL] [Abstract][Full Text] [Related]
34. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
[TBL] [Abstract][Full Text] [Related]
35. The telomere maintenance mechanism spectrum and its dynamics in gliomas.
Kim S; Chowdhury T; Yu HJ; Kahng JY; Lee CE; Choi SA; Kim KM; Kang H; Lee JH; Lee ST; Won JK; Kim KH; Kim MS; Lee JY; Kim JW; Kim YH; Kim TM; Choi SH; Phi JH; Shin YK; Ku JL; Lee S; Yun H; Lee H; Kim D; Kim K; Hur JK; Park SH; Kim SK; Park CK
Genome Med; 2022 Aug; 14(1):88. PubMed ID: 35953846
[TBL] [Abstract][Full Text] [Related]
36. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk
Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J
Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674
[No Abstract] [Full Text] [Related]
37. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
38. Assessment of NMYC amplification: a comparison of FISH, quantitative PCR monoplexing and traditional blotting methods used with formalin-fixed, paraffin-embedded neuroblastomas.
Layfield LJ; Willmore-Payne C; Shimada H; Holden JA
Anal Quant Cytol Histol; 2005 Feb; 27(1):5-14. PubMed ID: 15794447
[TBL] [Abstract][Full Text] [Related]
39. Correlation Between
Santiago T; Tarek N; Boulos F; Hayes C; Jeha S; Raimondi S; Rodriguez-Galindo C
J Glob Oncol; 2019 Jul; 5():1-7. PubMed ID: 31365300
[TBL] [Abstract][Full Text] [Related]
40. FOXR2 Stabilizes MYCN Protein and Identifies Non-
Schmitt-Hoffner F; van Rijn S; Toprak UH; Mauermann M; Rosemann F; Heit-Mondrzyk A; Hübner JM; Camgöz A; Hartlieb S; Pfister SM; Henrich KO; Westermann F; Kool M
J Clin Oncol; 2021 Oct; 39(29):3217-3228. PubMed ID: 34110923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
